TABLE 1.

Characteristics of included studies.

Authors (ref)	Publication year	Sample size (control/intervention)	Country/population	Intervention group	Duration of treartment	Duration of follow-up	Study design	Age (control, intervention)	Presented data
Chen et al. (2015)	2015	7/9	China/DM acute ST-segment elevation myocardial infarction (STEMI) undergoing primary PCI	Liraglutide (0.6 mg once daily for 2 days (1.6 pmol/kg per minute), 1.2 mg for another 2 days (3.2 pmol/kg per minute), and 1.8 mg for 3 days (4.8 pmol/kg per minute))	1 week a	12 weeks	Single-center, randomized, double-blind, placebo, controlled trial	59.2 ± 14.4 57.7 ± 11.3	BMI, HbA1C, SBP, DBP, and HR
Chen et al. (2015)	2015	40/36	China/NDM acute ST-segment elevation myocardial infarction (STEMI) undergoing primary PCI	Liraglutide (0.6 mg once daily for 2 days (1.6 pmol/kg per minute), 1.2 mg for another 2 days (3.2 pmol/kg per minute), and 1.8 mg for 3 days (4.8 pmol/kg per minute))	1 weeka	12 weeks	Single-center, randomized, double-blind, placebo, controlled trial	59.2 ± 14.4 57.7 ± 11.3	BMI, HbA1C, SBP, DBP, and HR
Chen et al. (2016)	2016	45/45	China/Non-STsegment elevation myocardial infarction (NSTEMI)	Liraglutide (0.6 mg once daily for 2 days, 1.2 mg liraglutide for another 2 days, followed by 1.8 mg liraglutide for 3 days)injection	1 week a	12 weeks	Single-center, randomized, double-blind, placebo, controlled trial	59.0 ± 12.1 58.0 ± 11.7	BMI, HbA1C, SBP, DBP, HR, TG, TC, HDL-C, and LDL-C
Kumarathurai et al. (2016)	2016	30	Denmark/Patients with CAD and T2D	0.6 mg liraglutide (injection) od + 500 mg metformin (tablet) bid was increased after 14 days to 1.2 mg od + (1,000 mg + 500 mg) daily and to 1.8 mg od + 1,000 mg bid after 28 days	12 weeks	12 weeks	Randomized, double-blind, placebo-controlled 12 plus 12 weeks crossover study	61.8 ± 7.6	BMI, WC, HbA1C, SBP, DBP, HR, and LDL-C
Kumarathurai et al. (2017)	2017	24	Denmark/Overweight patients with newly diagnosed T2D and stable CAD	0.6 mg liraglutide once daily (o.d.) + 500 mg metformin twice daily (b.i.d.) was increased after 14 days to liraglutide 1.2 mg o.d.+ metformin (1000 mgþ500 mg) and to 1.8 mg o.d. + 1000  mg B.i.d. after 28 days	12 weeks	12 weeks	Randomized, double-blind, placebo-controlled, crossover study	62.5 + 7.2	WC, HbA1C, SBP, and DBP
Anholm et al. (2017)	2017	30	Denmark/Overweight patients with CAD and newly diagnosed T2D	Liraglutide (1.8 mg once daily (titrated from 0.6 to 1.8 mg during 4 weeks)) + metformin (1 g twice daily (titrated from 500 mg to 1 g during 4 weeks))	12 weeks	12 weeks	Investigator-initiated, double-blinded, randomized, placebo-controlled, crossover trial	62.3 ± 7.6	BMI, WC, and HbA1C
Anholm et al. (2019)	2019	28	Denmark/Patients with CAD and newly diagnosed T2D	Liraglutide once daily was titrated from 0.6 to 1.8 mg within 4 weeks and metformin was titrated from 500 mg twice daily to 1 g twice daily in 4 weeks	12 weeks	12 weeks	Investigator-initiated, double-blind, randomized, placebo-controlled, cross-over trial	62.3 ± 7.6	TG, TC, HDL-C, and LDL-C

Abbreviations: CAD, coronary artery disease; Non-DM, Non-diabetes mellitus; DM, diabetes mellitus; T2D, type 2 diabetes; PCI, percutaneous coronary intervention; BMI, body mass index; WC, waist circumference; HR, heart rate; HDL-C, high density lipoprotein-cholesterol; LDL-C, low density lipoprotein-cholesterol; TG, triglycerides; TC, total cholesterol; HbA1C, hemoglobin A1C; SBP, systolic blood pressure; DBP, diastolic blood pressure.

^aDuration of the follow-up was 12 weeks.